최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기藥劑學會誌 = Journal of Korean pharmaceutical sciences, v.38 no.1, 2008년, pp.39 - 43
송충길 (서울대학교 약학대학) , 정석재 (서울대학교 약학대학) , 심창구 (서울대학교 약학대학) , 김대덕 (서울대학교 약학대학)
Cyclosporin A (CyA), a potent immunosuppressive drug used in allogeneic transplants and autoimmune disease, is a typical water-insoluble drug. Recently, nanoparticle carriers were investigated to improve the intestinal absorption of drugs. In this study, CyA-loaded nanostructured lipid carriers (NLC...
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
J.L. Italia, V. Bhardwaj and M.N.V.R. Kumar, Diease, destination, dose and delivery aspects of ciclosporin: the state of the art, Drug Disco. Today, 11, 846-854 (2006)
D. Faulds, K.L. Goa and P. Benfield, Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders, Drugs, 45, 953-1040 (1993)
N.E. Taylor, A.E. Mark, P. Vallat, R.M. Brunne, B. Testa and W.F. Van Gunteren, Solvent dependent conformation and hydrogen bounding capacity of cyclosporin A: evidence from partition coefficient and molecular dynamics simulations, J. Med. Chem., 36, 3753-3764 (1993)
J.L. Italia, D.K. Bhatt, V. Bhardwaj, K. Tikoo and M.N.V. Ravi Kumar, PLGA nanoparticles for oral delivery of cyclosporine: Nephrotoxicity and pharmacokinetic studies in comparison to Sandimmune Neoral $^{\circledR}$ , J. Control. Release, 119, 197-206 (2007)
M.H. El-Shabouri, Positively charged nanoparticles for improving the oral bioavailability of cyclosporin-A, Int. J. Pharm., 249, 101-108 (2002)
E. Ugazio, R. Cavalli and M.R. Gasco, Incorporation of cyclosporin A in solid lipid nanoparticles, Int. J. Pharm., 241, 341-344 (2002)
P.J. Carrigan and T.R. Bates, Biopharmaceutics of drugs administered in lipid-containing dosage forms I: GI absorption of griseofulvin from an oil-in-water emulsion in the rat, J. Pharm. Sci., 62, 1476-1479 (1973)
J.F. Pinto and R.H. Muller, Pellets as carriers of solid lipid nanoparticles ( $SLN^{TM}$ ) for oral administration of drugs, Pharmazie, 54, 506-509 (1999)
K. Manjunath, V. Venkateswarlu, Pharmacokinetics, tissue distribution and bioavailability of nitrendipine solid lipid nanoparticles after intravenous and intraduodenal administration, J. Drug Target., 14, 632-645 (2006)
M. Radtke and R.H. Muller, NLC-nanostructured lipid carriers: the new generation of lipid drug carriers, New Drugs, 2, 48-52 (2001)
R.H. Muller, M. Radtke and S.A. Wissing, Nanostructured lipid matrices for improved microencapsulation of drugs, Int. J. Pharm., 242, 121-128 (2002)
L. Hu, X. Tang and F. Cui, Solid lipid nanoparticles (SLNs) to improve oral bioavailability of poorly soluble drugs, J. Pharm. Pharmacol., 56, 1527-1535 (2004)
Y. Li, K.J. Zhu, J.X. Zhang, H.L. Jiang, J.H. Liu, Y.L. Hao, H. Yasuda, A. Ichimaru and K. Yamamoto, In vitro and in vivo studies of cyclosporin A-loaded microspheres based on copolymers of lactide and epsilon-caprolactone: comparison with conventional PLGA microspheres, Int. J. Pharm., 295, 67-76 (2005)
C. Washington, Stability of lipid emulsions for drug delivery, Adv. Drug Deliv. Rev., 20, 131-145 (1996)
K. Jores, W. Mehnert, M. Drechsler, H. Bunjes, C. Johann and K. Mader, Investigations on the structure of solid lipid nanoparticles (SLN) and oil-loaded solid lipid nanoparticles by photon correlation spectroscopy, field-flow fractionation and transmission electron microscopy, J. Control. Release, 95, 217-227 (2004)
J.X. Wang, X. Sun and Z.R. Zhang, Enhanced brain targeting by synthesis of 3',5'-dioctanoyl-5-fluoro-2'-deoxyuridine and incorporation into solid lipid nanoparticles, Eur. J. Pharm. Biopharm., 54, 285-290 (2002)
Cyclosporin emulsions, US Patent 5660858 (1997)
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.